Dare Bioscience, Inc. Amortization of Debt Issuance Costs
Dare Bioscience, Inc. (DARE) reported Amortization of Debt Issuance Costs of $135.87 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2025-11-13
- Dare Bioscience, Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $124.25K.
- Dare Bioscience, Inc. amortization of debt issuance costs for the quarter ending 2025-06-30 was -$5.91K, a 127.86% decline year-over-year.
- Dare Bioscience, Inc. amortization of debt issuance costs for the quarter ending 2025-03-31 was $17.53K, a 2560.39% increase year-over-year.
- Dare Bioscience, Inc. amortization of debt issuance costs for the quarter ending 2024-09-30 was $0.00.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month |
|---|---|---|---|
| 2025-09-30 | $124.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $118.34K derived: sum of 2 quarters · filed 2025-11-13 | $135.87K 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$5.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $11.62K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $17.53K 10-Q · filed 2025-05-13 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $21.22K derived: sum of 2 quarters · filed 2025-11-13 | $21.88K 10-Q · filed 2025-11-13 |
| 2024-06-30 | $21.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $21.88K 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $659.00 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |